09 Apr 2024 Christina Coughlin – AACR 2024 – AVA6000 data presentation Blogs | Investors | Therapeutics
09 Apr 2024 Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses Investors | Therapeutics